LeMaitre Vascular (LMAT) Stock Rating Lowered by ValuEngine

Share on StockTwits

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Thursday, June 21st.

LMAT has been the topic of a number of other reports. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, March 9th. Benchmark raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Thursday, April 26th. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, April 28th. Canaccord Genuity reiterated a “hold” rating and issued a $33.00 price objective on shares of LeMaitre Vascular in a research report on Friday, February 23rd. Finally, Stifel Nicolaus lowered LeMaitre Vascular from a “buy” rating to a “hold” rating and cut their price objective for the stock from $40.00 to $34.00 in a research report on Thursday, April 26th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $37.71.

LeMaitre Vascular opened at $34.43 on Thursday, Marketbeat Ratings reports. LeMaitre Vascular has a fifty-two week low of $26.37 and a fifty-two week high of $41.28. The firm has a market cap of $694.28 million, a PE ratio of 40.85, a PEG ratio of 2.20 and a beta of 0.57.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.02). The company had revenue of $25.99 million during the quarter, compared to the consensus estimate of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.16 EPS. research analysts forecast that LeMaitre Vascular will post 1.09 earnings per share for the current fiscal year.

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 35,000 shares of the company’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $34.50, for a total value of $1,207,500.00. Following the completion of the sale, the chief executive officer now owns 3,086,623 shares in the company, valued at $106,488,493.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman George W. Lemaitre sold 15,000 shares of the company’s stock in a transaction dated Tuesday, June 19th. The stock was sold at an average price of $37.07, for a total value of $556,050.00. Following the completion of the sale, the chairman now owns 3,073,802 shares of the company’s stock, valued at approximately $113,945,840.14. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,598 shares of company stock valued at $4,144,663. 20.30% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LMAT. Advisor Group Inc. boosted its stake in LeMaitre Vascular by 28.3% during the fourth quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock valued at $223,000 after buying an additional 1,550 shares during the last quarter. Swiss National Bank boosted its stake in LeMaitre Vascular by 6.8% during the first quarter. Swiss National Bank now owns 26,600 shares of the medical instruments supplier’s stock valued at $964,000 after buying an additional 1,700 shares during the last quarter. Sapphire Star Partners LP raised its position in LeMaitre Vascular by 18.1% during the first quarter. Sapphire Star Partners LP now owns 12,431 shares of the medical instruments supplier’s stock valued at $450,000 after purchasing an additional 1,906 shares during the period. Rhumbline Advisers raised its position in LeMaitre Vascular by 3.7% during the fourth quarter. Rhumbline Advisers now owns 60,673 shares of the medical instruments supplier’s stock valued at $1,932,000 after purchasing an additional 2,138 shares during the period. Finally, Victory Capital Management Inc. raised its position in LeMaitre Vascular by 73.8% during the first quarter. Victory Capital Management Inc. now owns 5,076 shares of the medical instruments supplier’s stock valued at $184,000 after purchasing an additional 2,156 shares during the period. 72.87% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply